Antiplatelet medications in hemodialysis patients: A systematic review of bleeding rates

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 8, 2009, Pages 1347-1355

  Hiremath, Swapnil ^a   Holden, Rachel M ^b   Fergusson, Dean ^c   Zimmerman, Deborah L ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; SULFINPYRAZONE; TICLOPIDINE; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CASE STUDY; CATHETER THROMBOSIS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; EMBASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMARTHROSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRESCRIPTION; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHUNT THROMBOSIS; SUBDURAL HEMATOMA; SYSTEMATIC REVIEW; THROMBOSIS; UPPER GASTROINTESTINAL BLEEDING; VASCULAR ACCESS; ARTERIOVENOUS SHUNT; BLOOD; BLOOD VESSEL TRANSPLANTATION; CENTRAL VENOUS CATHETERIZATION; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ARTERIOVENOUS SHUNT, SURGICAL; BLOOD VESSEL PROSTHESIS IMPLANTATION; CATHETERIZATION, CENTRAL VENOUS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; PLATELET AGGREGATION INHIBITORS; RENAL DIALYSIS; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

EID: 70349909734     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00810209     Document Type: Review

References (45)

1. Quinton W, Dullard D, Scribner BH: Cannulation of blood vessels for prolonged hemodialysis. Trans Am Soc Artif Intern Organs 6: 104-113, 1960
2. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7(4): 523-535, 1996
3. Reisman D: Hemorrhages in the course of Bright's disease, with especial reference to the occurrence of a hemorrhage diathesis of nephritic origin. Am J Med Sci 134: 709-712, 1907
4. Kaw D, Malhotra D: Platelet dysfunction and end-stage renal disease. Semin Dial 19: 317-322, 2006
5. Castillo R, Lozano T, Escolar G: Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 68: 337-342, 1986
6. P.K.B. Jaminidar In: AR FRGD Nissenson, Editor, Gastrointestinal disease in patients with chronic renal failure, chapter 26 in clinical dialysis vol. 3, East Norwalk, Appleton & Lange, 1995, pp. 607-617
7. Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K: Evidence for high risk of cerebral haemorrhage in chronic dialysis patients. Kidney Int 44: 1086-1090, 1993
8. Milutinovich J, Follette WC, Scribner BH: Spontaneous retroperitoneal bleeding in patients on chronic hemodialysis. Ann Intern Med 86: 189-192, 1977
9. Smetana SS, David E, Pelet D, Bar-Khayim Y: Subcapsular liver hematoma in a patient on chronic hemodialysis. Nephron 45: 323-324, 1987
10. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1: 414-416, 1986
11. Garcia Rodriguez LA, Hernandez-Diaz S, De Abajo FJ: Association between aspirin and upper gastrointestinal bleeding complications: Systematic review of epidemiological studies. Br J Clin Pharmacol 52: 563-571, 2001
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002
13. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI; Dialysis Access Consortium Study Group: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 299(18): 2164-2171, 2008
14. Hasegawa T, Elder SJ, Bragg-Gresham JL, Pisoni RL, Yamazaki S, Akizawa T, Jadoul M, Hugh RC, Port FK, Fukuhara S: Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol 3(5): 1373-1378, 2008
15. Elliott MJ, Zimmerman D, Holder RM: Warfarin anti-coagulation in hemodialysis patients: A systematic review of bleeding rates. Am J Kidney Dis 50: 433-440, 2007
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12, 1996
17. Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M: The role of sulfinpyrazone in the prevention of arteriovenous shunt thrombosis. Circulation 52: 497-499, 1975
18. Kobayashi K, Maeda K, Koshikawa S: Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis. J New Remedies & Clinics 28: 1032-1049, 1979
19. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA: Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 301: 577-579, 1979
20. Kobayashi K, Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, Naito C: Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis-A multicenter collaborative double blind study. Thrombosis Research 20: 255-261, 1980
21. Domoto DT, Bauman JE, Joist JH: Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thrombosis Research 62: 737-743, 1991
22. Kooistra MP, van Es A, Marx JJ, Hertsig ML, Struyvenberg A: Low-dose aspirin does not prevent thrombovascular accidents in low-risk hemodialysis patients during treatment with erythropoietin. Nephrol Dial Transplant 9: 1115-1120, 1994
23. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 45: 1477-1483, 1994
24. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN; Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis: For the veterans affairs cooperative study group on hemodialysis access graft thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14: 2313-2321, 2003
25. Obialo CI, Conner AC, Lebon LF: Maintaining patency of tunneled hemodialysis catheters. Scand J Urol Nephrol 37: 172-176, 2003
26. Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO: Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 64: 1455-1461, 2003
27. Trimarchi H, Young P, Forrester M, Schropp J, Pereyra H, Freixas E: Clopidogrel diminishes hemodialysis access graft thrombosis. J Vascular Access 6: 29-33, 2005
28. Coli L, Donati G, Cianciolo G, Raimondi C, Comai G, Panicali L, Nastasi V, Cannarile DC, Gozzetti F, Piccari M, Stefoni S: Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheter thrombosis. J Vascular Access 7: 118-122, 2006
29. Abdul-Rahman IS, Al-Howaish AK: Warfarin versus aspirin in prevention tunneled hemodialysis catheter thrombosis: A prospective randomized study. Hong King J Nephrol 9: 23-30, 2007
30. Ethier J, Bragg-Gresham JL, Piera L, Akizawa T, Asano Y, Mason N, Gillespie BW, Young EW: Aspirin prescription and outcomes in hemodialysis patients: The dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 50: 602-611, 2007
31. Holden RM, Harman GJ, Wang M, Holland D, Day AG: Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3: 105-110, 2008
32. To AC, Yehia M, Collins JF: Atrial fibrillation in hemodialysis patients: Do the guidelines apply? Nephrology 12: 441-447, 2007
33. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 7; 110: 1202-1208, 2004
34. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA; American College of Chest Physicians: The primary and secondary prevention of coronary artery disease: American college of chest physicians evidence-based clinical practice guidelines. Chest 133: 776-814, 2008
35. Casterella PJ, Tcheng JE: Review of the 2005 American college of cardiology, American heart association, and society for cardiovascular interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: Practical implications, new clinical data, and recommended guideline revisions. Am Heart J 155: 781-790, 2008
36. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW; Dialysis Outcomes and Practice Patterns Study: Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40: 1255-1263, 2002
37. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ; CREDO Investigators: The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events during Observation (CREDO) Trial. Am Heart J 155: 687-693, 2008
38. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, Mehta SR, Yusuf S; CURE Trial Investigators: Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 14: 312-318, 2007
39. Lohr J, Schwab S: Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 2: 961-975, 1991
40. Biggers JA, Remmers AR Jr, Glassford DM, Sarles HE, Lindley JD, Fish JC: The risk of anticoagulation in hemodialysis patients. Nephron 18: 109-113, 1977
41. Vázquez E, Sánchez-Perales C, García-Cortes MJ, Borrego F, Lozano C, Guzmán M, Gil JM, Liébana A, Pérez P, Borrego MJ, Pérez V: Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol 87: 135-139, 2003
42. Foley RN, Curtis BM, Parfrey PS: Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol 3: 1669-1675, 2008
43. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Proceedings of the 3rd Symposium on Systematic Reviews. Beyond the basics: Improving quality and impact; 2000 July 3-5, Oxford. Oxford, 2000
44. Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ; CHARISMA Investigators: On behalf of the CHARISMA investigators: Aspirin to prevent cardiovascular disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Ann Intern Med 150: 379 -386, 2009
45. Chan KE, Lazarus JM, Thadhani R, Hakim RM: Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20: 872-881, 2009